HOPE-Neuron therapeutx

First Therapeutic Targets: ALS & Parkinson's

A new approach to treat neurodegenerative conditions

HOPE-Neuron Therapeutx is a U.S.-based, mission driven company that has developed a cell-based, non-pharma technology (AIMtx™) that activates the body's own immune system to fight disease through immune balancing and healing, anti-inflammation, and the normalization of imbalanced disease cells. Our initial ALS mouse studies indicate that our novel therapy works -- and most importantly -- have demonstrated the effectiveness of AIMtx™ in significantly extending life in these test animals. Based on the success of this historic and pioneering advancement, we are now seeking funding to continue our research and move towards scheduled human trials, with a goal of accelerated clinical FDA approval and possible treatment use in 2025.

Frequently Asked Questions

Please contact us if you have additional questions.

What makes HOPE-Neuron different from other companies battling autoimmune neurodegenerative diseases?

To date, virtually all approved and studied solutions to treat ALS and other neurodegenerative diseases have been pharmacological in nature. HOPE-Neuron’s AIMtx™ technology is radically different because it is device-based, conditioning a patient’s own blood to promote healing.

How does AIMtx™ work?

AIMtx™ creates an apoptogenic shift using a patient’s own blood to switch cells from killing mode (M1) to healing Mode (M2), thereby rebalancing a person’s body away from damaging inflammation and dysregulated function and into normalized cell health.

How will AIMtx™ be administered?

The HOPE-Neuron AIMtx™ treatment will involve taking a small quantity (a little more than ½ cup) of a patient’s own blood, conditioning this blood through the company’s AIMtx™ device, then reinfusing this treated blood back into the patient. Because there is no off-site processing, the therapy is expected to take about 30 minutes and can be administered on an out-patient basis. Currently, the company’s initial estimate is that this regimen will involve 3 treatments per year for a typical patient.

What are the side effects?

The process does not use any pharmaceuticals or toxic chemicals, so there are no known side effects.

When will the HOPE-Neuron treatment be available?

In 2024, HOPE-Neuron completed an important mouse trial at Indiana University that translated to humans indicated the therapy could prolong the life of ALS patients. Because this is a non-pharma, device-based solution with an excellent safety profile, the pathway to human trials could be very fast -- potentially within a year of the next clinical study.

Why haven’t I heard of this treatment or technology before now?

Although the company’s research dates back more than a decade, in its current form HOPE-Neuron has been largely self-funded (friends and family) and has operated primarily as a stealth operation focused on R&D. The success of the 2024 ALS mouse study has created an urgency to move quickly to human trials. Management believes that further progress may earn the company fast track status.

What does HOPE-Neuron need to move forward?

Our pathway is set, with additional studies already planned and research partners in place. Our limiting factor is simply funding. To expedite this process, we are calling out to the ALS and Parkinson’s communities to help fund the next phase of our research.

How You can Help

Every day counts

Our recent success is the result of years of hard work by a dedicated team that followed a truly novel path in pursuit of non-pharma therapies for autoimmune-neurodegenerative diseases such as ALS and Parkinson’s. To date, a majority of our funding has come from friends and family, but with our recent success in the lab, we have a new sense of urgency to expedite our trials. Every day makes a difference.

Help us today

We appreciate your help in our mission to bring new HOPE to the ALS and Parkinson's communities.

Donate Now

About HOPE-Neuron therapeutx

Our Mission

At HOPE-Neuron therapeutx, our mission is to develop a safe, effective platform technology for the treatment of autoimmune neurodegenerative diseases.

Our Request

Our Mission

We are looking to partner with organizations that sponsor research on autoimmune neurodegenerative conditions (such as ALS, Parkinson's, MS and Alzheimer's) -- for both funding and support as we expedite our timeline toward human trials.

Our HOPE

Our Mission

Our HOPE

HOPE is born from curiosity that inspires action -- and in our case, that represents years of study that led our team to ALS. Our AIMtx™ device-enabled technology represents a truly unique path forward, with a potentially quick regulator timeline.